Search

Your search keyword '"Pijnenburg, Yolande a.L."' showing total 698 results

Search Constraints

Start Over You searched for: Author "Pijnenburg, Yolande a.L." Remove constraint Author: "Pijnenburg, Yolande a.L."
698 results on '"Pijnenburg, Yolande a.L."'

Search Results

4. Prioritization of Drug Targets for Neurodegenerative Diseases by Integrating Genetic and Proteomic Data From Brain and Blood

6. The Benson Complex Figure Test detects deficits in visuoconstruction and visual memory in symptomatic familial frontotemporal dementia: A GENFI study

7. Spatial distributions of white matter hyperintensities on brain MRI: A pooled analysis of individual participant data from 11 memory clinic cohorts

9. Everyday functioning in young onset dementia: differences in diagnostic groups independent of disease stage.

10. Comparing and linking the Mini-Mental State Examination and Montreal Cognitive Assessment in the Amsterdam Dementia Cohort.

12. Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes

14. Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer’s disease subgroups

16. Distinctive cell-free DNA methylation characterizes presymptomatic genetic frontotemporal dementia

17. Visual associative learning to detect early episodic memory deficits and distinguish Alzheimer's disease from other types of dementia.

18. Rationale and Design of the “DIagnostic and Prognostic Precision Algorithm for behavioral variant Frontotemporal Dementia” (DIPPA-FTD) Study: A Study Aiming to Distinguish Early Stage Sporadic FTD from Late-Onset Primary Psychiatric Disorders

21. Differential Expression of Synaptic Biomarkers in the Cerebrospinal Fluid Differentiates Behavioural Variant of Frontotemporal Dementia from Primary Psychiatric Disorders and Alzheimer’s Disease

22. Automated FreeSurfer segmentation and visual quality control in 10,000 MRI scans from a large memory clinic cohort

24. Individualised prognostic models using plasma biomarkers for clinical progression to Alzheimer’s disease dementia in non‐demented elderly

25. CSF proteomics in autosomal dominant Alzheimer’s disease highlights parallels with sporadic disease

28. Tau‐PET signal in Alzheimer’s disease is related to immune activation and synaptic signaling measured with CSF proteomics

29. Visual rating scales of atrophy to differentiate Frontotemporal dementia from Primary psychiatric disorder: results from DIPPA study

30. Plasma protein profiling reveals novel specific biomarkers reflecting the multifactorial nature of Alzheimer´s disease continuum

31. Impact of sharing Alzheimer’s disease biomarker results with individuals without dementia: a systematic review and meta‐analysis of empirical data

32. Computerized decision support is an effective approach to select memory clinic patients for amyloid‐PET

34. Mastermind of the Alzheimer’s blood‐based biomarkers: development of cutoffs and a visualization tool for use in clinical practice

35. Premorbid musical experience influences socio‐emotional functioning in behavioural variant frontotemporal dementia

36. Data driven criteria for genetic testing result in an efficient selection of patients with genetic dementia in a clinical setting

37. Data‐driven analysis of most common neurodegenerative dementias reveals atrophy patterns associated with overlapping cognitive symptoms

38. Amygdala volume as neuroimaging marker of limbic‐predominant age‐related TDP‐43 encephalopathy (LATE) in neurodegenerative disease: a post‐mortem MRI and pathology study

40. Factors modifying the association between blood‐based biomarkers for Alzheimer’s disease and amyloid status

41. Can escapees of familial AD help identify protective factors? A case report of an extremely resilient PSEN1 carrier

43. Motor neuron symptoms and pathology burden in de medulla oblongata of FTLD‐TDP brain donors

45. ABOARD Cohort; a national initiative to involve citizens in AD research

46. CSF proteome profiling identifies novel biomarkers for Frontotemporal Dementia and its pathological subtypes

47. Plasma pTau181 and biomarker combinations to identify Alzheimer´s disease at any stage along the AD continuum compared with both controls and non‐AD dementia

50. TREM2 AD risk variants impact pTau and microglia and astrocyte related biomarkers in cognitively unimpaired subjects

Catalog

Books, media, physical & digital resources